Keppra 500mg 60 Tablets: Effective Epilepsy Management in Nigeria
Keppra 500mg is a brand-name antiepileptic medication containing Levetiracetam. It is a prescription-only medicine (POM) used to control various types of seizures in adults and children, including partial-onset, myoclonic, and primary generalized tonic-clonic seizures.
As a trusted anticonvulsant, Keppra works by stabilizing electrical activity in the brain, helping to reduce the frequency and intensity of seizure episodes.
How Levetiracetam (Keppra) Works
Each film-coated tablet contains 500mg of Levetiracetam. This active ingredient modulates neurotransmitter release in the brain. Whether used as monotherapy (on its own) or adjunctive therapy (with other medicines), it helps manage epilepsy symptoms effectively.
What is Keppra 500mg Used For?
In clinical practice in Nigeria, Keppra is prescribed for:
- Partial-Onset Seizures: Seizures starting in a specific area of the brain.
- Myoclonic Seizures: Brief, involuntary muscle jerks.
- Generalized Tonic-Clonic Seizures: Seizures involving the whole brain.
Dosage and Administration
Keppra tablets should be swallowed whole with water and can be taken with or without food. Usually, the total daily dose is split into two—morning and evening.
Important Safety Note: Never stop taking Keppra or any seizure medication abruptly, as this can trigger more frequent or severe seizures. If you have questions about your prescription, you can contact a GoMed pharmacist for expert guidance.
Side Effects and Precautions
Commonly reported effects include drowsiness, dizziness, or mood changes, particularly when starting treatment. Avoid alcohol while taking this medication. If you are pregnant or planning to conceive, consult your healthcare provider immediately to discuss a safe management plan.
Manufacturer and Distribution
Keppra is manufactured by UCB Pharma S.A. in Belgium. While it was traditionally represented by GSK Consumer Nigeria PLC, the distribution in the Nigerian market has transitioned to a third-party model following GSK's operational changes in 2023.